Clinical trial
Chemotherapy in Treating Patients With Solid Tumors
NCT00003103 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00003103 |
|---|---|
| Title | Chemotherapy in Treating Patients With Solid Tumors |
| Official title | A Phase I/IIA Dose-Escalating Trial of BCL-2 Antisense (G3139) Treatment for Patients With Androgen-Independent Prostate Cancer or Other Advanced Solid Tumor Malignancies |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Bladder Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer, Unspecified Adult Solid Tumor and 1 more |
| Intervention type | Biological, Drug |
| Interventions | oblimersen sodium, docetaxel |
| Enrollment | 57 |
| Start date | Aug 1, 1997 |
| Primary completion | Aug 1, 2002 |
| Completion | Aug 1, 2002 |
| First posted | Apr 6, 2004 |
| Last update posted | Jul 3, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: